The Aging Population Drives Growth In Colorectal Cancer Screening Demand Emerges as a Core Driver of the Colorectal Cancer Screening Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Colorectal Cancer Screening Market Through 2025?
The market size for colorectal cancer screening has shown robust growth over the recent years. The growth is expected to continue, with the market size projected to increase from $15.61 billion in 2024 to $16.6 billion in 2025, realizing a compound annual growth rate (CAGR) of 6.3%. The remarkable growth experienced in the past can be credited to factors such as rising cases of colorectal cancer, heightened government-led awareness initiatives, an aging demographic, increasing utilization of colonoscopy procedures, and enhanced insurance coverage.

What's the Projected Size of the Global Colorectal Cancer Screening Market by 2029?
In the upcoming years, the colorectal cancer screening market is projected to witness significant expansion. The market is predicted to reach $21.01 billion by 2029, growing at a 6.1% compound annual growth rate (CAGR). The expected growth during this period can be ascribed to the transition towards non-invasive screening techniques, a higher number of home-based screening tests, an increased prevalence of obesity, the implementation of value-based healthcare, and growing public-private alliances. Noteworthy advancements expected in this forecast period include the incorporation of AI in screening and diagnostic procedures, extending screening guidelines to younger demographics, a wider application of genomic testing for cancer risks, the surge in mobile health (mHealth) platforms, and partnership efforts between pharmaceutical and diagnostic firms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-screening-global-market-report

Top Growth Drivers in the Colorectal Cancer Screening Industry: What's Accelerating the Market?
The growth of the colorectal cancer screening market is projected to be fuelled by the escalating aging population. The term aging population is used to describe a demographic shift where the ratio of senior citizens (usually aged 65 and up) rises compared to the population of working age, largely a result of longer lifespans and falling birth rates. Due to extended life spans and decreasing birth rates, the senior citizen segment of the global population is expanding. Colorectal cancer screening plays a crucial role in catering to the burgeoning aging population's requirements by facilitating early cancer diagnosis and mitigation strategies. This helps manage the heightened cancer risk in older adults, thereby improving their overall health. For example, the Population Reference Bureau (PRB), a non-profit research organization in the US, announced in January 2024 that the population of Americans aged 65 and above is projected to surge from 58 million in 2022 to 82 million by 2050, signifying a growth of 47%. Similarly, this demographic's share of the overall population is expected to rise from 17% to 23%. Hence, the escalating aging population is a key driver of the colorectal cancer screening market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19008&type=smp

What Trends Will Shape the Colorectal Cancer Screening Market Through 2029 and Beyond?
Key players in the colorectal cancer screening market are placing emphasis on the advancement of innovative techniques, like non-invasive multi-target stool ribonucleic acid (RNA) colorectal cancer screening tests. These tests are intended to provide a more accessible, efficacious approach to the early detection of colorectal cancer, enhance the survival rate of patients, and promote wider screening participation. This method of screening uncovers the existence of colorectal cancer or pre-malignant growths by scrutinizing RNA markers found in stool samples, thereby providing a non-surgical option for early detection. For example, in May 2024, the U.S.-based biotechnology firm, Geneoscopy Inc., declared that the U.S. Food and Drug Administration (FDA) approved their product named ColoSense. This product utilizes RNA biomarkers in a non-invasive, stool-based screening, showcasing a 93% sensitivity in identifying colorectal cancer and a 45% sensitivity in advanced adenoma detection. Its value comes from its high precision, notably in younger demographics, and its ability to boost screening participation through offering an alternative that's less invasive than conventional procedures.

What Are the Main Segments in the Colorectal Cancer Screening Market?
The colorectal cancer screeningmarket covered in this report is segmented -

1) By Type: Stool-Based, Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Stool Deoxyribonucleic Acid (DNA) Test, Colonoscopy, Other Types
2) By Age Group: Below 50 Years, 50-64 Years, Above 65 Years
3) By End User: Hospitals And Clinics, Clinical Laboratories, Diagnostic Imaging Centers, Other End-Users

Subsegments:
1) By Stool-Based Tests: Stool-Based Tests
2) By Fecal Immunochemical Test (FIT): High-Sensitivity FIT, Low-Sensitivity FIT
3) By Fecal Occult Blood Test (FOBT): Guaiac FOBT, Immunochemical FOBT
4) By Stool Deoxyribonucleic Acid (DNA) Test: Multi-Target Stool DNA Test, Single-Target Stool DNA Test
5) By Colonoscopy: Diagnostic Colonoscopy, Therapeutic Colonoscopy
6) By Other Types: Virtual Colonoscopy, Flexible Sigmoidoscopy, Capsule Endoscopy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19008&type=smp

Which Top Companies are Driving Growth in the Colorectal Cancer Screening Market?
Major companies operating in the colorectal cancer screening market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, FUJIFILM Holdings Corporation, GE HealthCare, Boston Scientific Corporation, Olympus Corporation, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., Eiken Chemical Co. Ltd., HemoCue AB, Clinical Genomics Inc., Polymedco LLC, Hemosure Inc., Geneoscopy Inc., Novigenix SA

Which Regions Will Dominate the Colorectal Cancer Screening Market Through 2029?
North America was the largest region in the colorectal cancer screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19008

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.